NCEL
NewcelX Ltd.
NASDAQ: NCEL · HEALTHCARE · BIOTECHNOLOGY
$3.30
-2.23% today
Updated 2026-09-11
Market cap
$19.52M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.25
Dividend yield
—
52W range
$2 – $25
Volume
0.0M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.5
Quality
C3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-10.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$23.00
+596.02%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.05x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -10.11 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-1984.00
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Net income | $-16.50M | $-12.17M | $-1.98M | $-8.30M | $4.35M |
| EPS | — | — | — | — | $-2.25 |
| Free cash flow | $-14.52M | $-9.68M | $-4.27M | $-2.77M | $-1984.00 |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
NewcelX Ltd. trades at $3.30. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -10.11, it sits in the distress.
Frequently asked questions
What is NewcelX Ltd.'s stock price?
NewcelX Ltd. (NCEL) trades at $3.30.
Is NewcelX Ltd. overvalued?
NewcelX Ltd. carries a Smart Value Score of 22/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of NewcelX Ltd. (NCEL)?
The 12-month analyst consensus target is $23.00, about 596.0% above the current $3.30. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
NewcelX Ltd.'s Altman Z-Score is -10.11, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-58.01%
Beta0.57
50D MA$3.57
200D MA$3.11
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—